Low Dose Rapamycin in ME/CFS, Long-COVID, and Other Infection Associated Chronic Conditions
Sponsor: Bateman Horne Center, Salt Lake City, UT
Listed as NCT06257420, this observational or N/A phase trial focuses on Long-COVID and Myalgic Encephalomyelitis and remains ongoing. Sponsored by Bateman Horne Center, Salt Lake City, UT, it has been updated 5 times since 2023, reflecting limited change activity. This study is part of the global effort to build evidence for infectious disease interventions.
Status Flow
Change History
5 versions recorded-
Dec 2024 — Present [monthly]
Enrolling By Invitation
-
Sep 2024 — Dec 2024 [monthly]
Enrolling By Invitation
-
Jul 2024 — Sep 2024 [monthly]
Enrolling By Invitation
-
May 2024 — Jul 2024 [monthly]
Enrolling By Invitation
-
Mar 2024 — May 2024 [monthly]
Enrolling By Invitation
First recorded
Dec 2023
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Bateman Horne Center, Salt Lake City, UT
- Center For Complex Diseases-Seattle, WA
- Center for Complex Diseases- Palo Alto, CA
- Mayo Clinic
- Sierra Internal Medicine, Incline Village, NV
- Simmaron Research Inc.
- Simmaron Research Inc. R&D Lab, University of Wisconsin, Milwaukee (UWM)
For direct contact, visit the study record on ClinicalTrials.gov .